What changed
$PFE — WATCHLIST 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $14.5B | EPS $0.75 vs $0.72 🟢
💡 Consensus expects sustained earnings erosion from looming patent expirations (Eliquis, Ibrance) and fading COVID revenues, but the Q1 beat and ex-COVID growth suggest the base business is more durable than feared. The market's 1st-percentile quant rank reflects overly pessimistic assumptions that could be proven wrong over time.
📉 Reward/risk: 2.3:1
🏢 Business Quality: 6/10
📊 Valuation: cheap — P/E ~8x vs 5-year avg 12x and pharma peers 15x; EV/EBITDA ~7x vs historical 10x; DCF suggests intrinsic value in the mid-$30s; range $20–$30...
🔮 Catalyst: Q2 2026 earnings (expected late July 2026)
💰 Entry: $24.04, stop $21.5, target $30
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/PFE0625